[Paradoxical cutaneous reactions associated with tocilizumab therapy].

Abstract

INTRODUCTION:

Tocilizumab (TCZ) is a humanized antihuman interleukin (IL)-6 receptor antibody recommended for the treatment of moderate to severe active rheumatoid arthritis, adult-onset Still disease, Castleman disease and more recently, systemic juvenile idiopathic arthritis. Like anti-TNFα, rituximab and less frequently abatacept, TCZ can induce paradoxical cutaneous eruption like psoriasis with predominantly palmoplantar presentation.

CASE REPORT:

We report a 47-year-old woman with psoriastic arthritis who developed under anti-TNFα therapy and later under tocilizumab a paradoxical palmoplantar eruption.

CONCLUSION:

The specific underlying mechanisms of this side effect are unclear but relapse of these lesions seems to be observed with certain biological agents.

• Authors: L Sparsa, N Afif, S Bularca, A Fricker, S Thiebault, E Dahan, D Wendling, J Sibilia, M Ardizzone
• Journal: La Revue de medecine interne (Rev Med Interne) Vol. 35 Issue 9 Pg. 613-6 (Sep 2014) ISSN: 1768-3122 [Electronic] France
• Vernacular Title: Réactions cutanées paradoxales sous traitement par tocilizumab.
• PMID: 24630585 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2014 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Chemical References

• Antibodies, Monoclonal, Humanized
• tocilizumab

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Arthritis, Psoriatic (drug therapy)
• Drug Eruptions (diagnosis)
• Female
• Humans
• Middle Aged